Latest Articles
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer - OncLive
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer OncLive
Published: Jan. 30, 2025, 10:54 p.m.
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? - Medscape
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? Medscape
Published: Jan. 21, 2025, 9:45 a.m.
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer - Physician's Weekly
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer Physician's Weekly
Published: Oct. 22, 2024, 6:31 a.m.
Pembrolizumab aids survival with high-risk endometrial cancer - Medical Xpress
Pembrolizumab aids survival with high-risk endometrial cancer Medical Xpress
Published: Oct. 21, 2024, 5:50 p.m.
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer - HealthDay
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer HealthDay
Published: Oct. 21, 2024, 3:35 p.m.
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint - Healio
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint Healio
Published: May 9, 2024, 7 a.m.
Molecular Classification May Predict Survival Outcomes in Endometrial Cancer - Oncology Learning Network
Molecular Classification May Predict Survival Outcomes in Endometrial Cancer Oncology Learning Network
Published: April 1, 2024, 7 a.m.
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy - The ASCO Post
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy The ASCO Post
Published: March 27, 2024, 6:45 p.m.
Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients - Nature.com
Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients Nature.com
Published: Feb. 22, 2024, 8 a.m.
Link copied to clipboard!